Allegro shares promising preclinical results for osteoarthritis treatment

Ella Day | March 26, 2025 | News story | Clinical Trial Services, Research and Development Allegro, Orthopaedics, biomedical, clinical studies, osteoarthritis 

Allegro has announced that hydrocelin, its injectable microparticle hydrogel, showed no signs of toxicity in two preclinical studies.

Allegro is a biomedical company that develops nanotechnology-based treatments for degenerative joint disease.

The preclinical studies were conducted in rats for periods of four and 13 weeks, respectively. Hydrocelin was injected into four separate locations, and a negative control group received saline solution. There was no evidence of systemic toxicity in either study.

Advertisement

Lucas Decuypere, Allegro’s chief executive officer, stated: “It is gratifying to be able to announce another set of positive results as we near a first-in-human testing for hydrocelin.

“Allegro is working tirelessly to give mobility back to the millions of people around the world whose life is severely impacted by osteoarthritis, a disease for which there is not currently a disease-modifying treatment. We believe the unique properties of hydrocelin, if confirmed in clinical studies, could be a huge step in achieving that goal.”

The positive safety results confirmed what the company had established in previously published preclinical studies. Allegro is planning a multi-centre clinical study later in 2025, preparing hydrocelin for osteoarthritis patients. Also, it intends on a commercial launch in 2027.

Ella Day
26/3/25

Related Content

Allegro confirms successful safety testing of osteoarthritis treatment

Allegro’s hydrocelin treatment for osteoarthritis has demonstrated a satisfactory safety profile, giving it potential to …

Santhera Pharmaceuticals announces LIONHEART study results for corticosteroid vamorolone

Santhera Pharma has announced the results of its LIONHEART study, which evaluated vamorolone – a …

Rheumatoid arthritis

Positive results announced for Levicept’s moderate-to-severe osteoarthritis treatment

Biotechnology company Levicept has announced positive results from its phase 2 trial into LEVI-04, for …

The Gateway to Local Adoption Series

Latest content